Your first 90 days
Your first 90 days on Rystiggo for generalized myasthenia gravis
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Rystiggo works in rounds of weekly doses rather than as a pill taken every day. Each cycle is 6 infusions a week apart, followed by a break whose length the neurologist sets from how your symptoms behave. The first 90 days usually hold one full cycle, the break after it and, for some people, the start of a second. This page lays out that stretch from the FDA label, UCB's ONWARD program and one insurer's written rules.
What has to happen before the first bottle ships
Rystiggo has no REMS, so the first dose waits on an insurance approval and a place where a healthcare provider can give the infusion. These are the 6 things in the way, in order.
Where each dose will happen
UCB lists an infusion center, a doctor's office or an outpatient hospital clinic as places to get Rystiggo.
- Infusions at home with a nurse may also be available, depending on your insurance coverage.UCB dosing page
A healthcare provider gives every dose
The label says only a healthcare provider should prepare and infuse Rystiggo, using an infusion pump.
- Staff watch you during the infusion and for 15 minutes afterward for signs of an allergic reaction.FDA label
Your antibody test and the paperwork
Rystiggo is approved for adults who test positive for AChR or MuSK antibodies.
- UCB's Start Form asks the office for the antibody lab report, clinic notes, your MG-ADL score and your medicine list.
- You sign the patient authorization pages of the same form.ONWARD Start Form
Vaccines, checked before each cycle
The label asks the doctor to check whether any age-appropriate vaccines are due before each new treatment cycle.
- Live vaccines are not recommended during treatment, because Rystiggo lowers the body's IgG antibodies.
- UCB says there is no vaccine requirement before the first dose.UCB FAQs
No active infection on dose day
The label says to delay a dose while an infection is active, until it has resolved.
- Tell the office about any fever, cough or burning when you urinate before you travel to the appointment.FDA label
The insurance approval, and ONWARD
Your plan first checks whether it covers Rystiggo and its infusion, and whether prior authorization is needed.
- UCB warns that offices may call from numbers you do not know during this stage.
- If a request is denied, your healthcare provider starts an appeal on your behalf.ONWARD insurance guide
The days that matter
Counted from the first dose, with the 6 weekly infusions of cycle 1, the vaccine check, and the earliest studied start of cycle 2. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form and the benefits check
The neurologist's office faxes or emails the ONWARD Start Form with your records.
- No source sets how long approval takes, since each insurer works on its own timeline.
The welcome call from ONWARD
Your Care Coordinator calls to introduce themselves and send resources for starting treatment.
- They also keep you updated while the benefits check and prior authorization move forward.
Approval, then the scheduling call
After approval, the infusion provider calls to book your first dose, or to ship the medicine for a home infusion.
- If a specialty pharmacy supplies it, the pharmacy asks for payment details for your share before it ships.
- If the clinic buys it, you are billed after the infusion.
First infusion of cycle 1
One dose this week, then 1 a week for 5 more weeks.
- UCB says the infusion takes about 15 minutes once prepared, followed by 15 minutes of watching for an allergic reaction.
Dose 2
Same dose, given on the same day of the week as the first one.
- If it is missed, the label allows it up to 4 days late, and then the original schedule resumes.
Dose 3
Headache was the most common side effect in the main trial, in 44% on Rystiggo against 19% on placebo.
- Severe headache occurred in 5.3% of people on Rystiggo and in no one on placebo.
Dose 4
Reactions where the needle went in occurred in 8% on Rystiggo against 3% on placebo.
- The label says they appeared within 1 to 3 days after an infusion.
Dose 5
In the trials, allergic reactions such as swelling and rash appeared anywhere from 1 day to 2 weeks after a dose.
- Tell your care team right away if one starts at home.
Dose 6, the last of cycle 1
This infusion ends cycle 1, and the break begins.
- The neurologist decides from a clinical evaluation when, and whether, another cycle is needed.
The trial's main check point
In the main trial, the MG-ADL daily activities score fell 3.4 points on Rystiggo by day 43, against 0.8 points on placebo.
- Higher scores on this 0 to 24 scale mean more trouble with daily tasks.
The break, and symptom tracking
UCB says Rystiggo works only during a treatment cycle, so watch for symptoms that return during the break.
- Tell your doctor about any change, since your notes help time the next cycle.
Vaccine check before the next cycle
The label asks the doctor to check due vaccines before every new cycle, not only the first one.
- Mention any shot you have had or planned since the last cycle.
Earliest studied start of cycle 2
Day 64 is 63 days after cycle 1 began, the shortest gap studied.
- In a longer study, people starting 4 cycles a year waited a median of 98 days between cycle starts.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Rystiggo label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Label dated October 23, 2026, read on DailyMed. FDA label
- December 2025
The FDA approved details of a pregnancy exposure registry and added shingles (herpes zoster) as a side effect reported since approval.FDA letter
- August 2025
The label's own list of recent changes dates a revision of its preparation and administration section to August 2025.FDA label
- May 2025
The DailyMed label has allowed a vial up to 20 days at room temperature since May 2025, where the June 2024 FDA copy said 30. The FDA's December 2025 copy of the label still says 30 days.FDA label, December 2025
- June 2024
Three new single-dose vial sizes were added, holding 420mg, 560mg and 840mg, so each weekly dose can come from one vial. Before this, Rystiggo came only as a 280mg vial.FDA label, June 2024
- June 2023
The FDA first approved Rystiggo for adults with generalized myasthenia gravis who test positive for AChR or MuSK antibodies.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- One infusion a week for 6 weeks, then a break
The label calls this run of 6 weekly doses a single treatment cycle.
- Later cycles are given according to clinical evaluation, which means the neurologist decides from your symptoms and side effects.FDA label
- How the dose is set
People under 50kg (about 110 lb) get 420mg, which is 3mL.
- From 50kg up to 100kg (about 220 lb) the dose is 560mg, or 4mL.
- People at 100kg or more get 840mg, which is 6mL.FDA label
- How each infusion is given
A small needle goes under the skin of the lower right or lower left belly, below the navel.
- Staff avoid tender, bruised, red or hard skin, tattoos, scars and stretch marks.
- The site changes with each infusion.FDA label
- If a dose is missed
The label allows a missed dose to be given up to 4 days after the scheduled day.
- After that, the original schedule resumes until the cycle is complete.FDA label
- Storage, if vials are delivered to you
The label keeps vials in the fridge at 36°F to 46°F (2°C to 8°C) in the original carton, never frozen or shaken.
- If needed, a vial can sit at room temperature up to 77°F (25°C) for a single stretch of up to 20 days.
- Once warmed, it does not go back in the fridge.
- The FDA's December 2025 copy of the label says 30 days, so the pharmacy can confirm which limit applies to your vials.FDA label
- Other antibody medicines
Rystiggo can lower the levels and weaken the effect of drugs that use the same FcRn receptor, such as immunoglobulin (IVIG) and some monoclonal antibodies.
- The label asks doctors to watch for this and, if long-term use of both is essential, to consider stopping Rystiggo.FDA label
- Your other myasthenia medicines
In the main trial, people joined while on stable doses of their usual myasthenia medicines, such as acetylcholinesterase inhibitors, steroids or other immune drugs.
- Any change to those medicines is a decision for your neurologist.FDA label
- Pregnancy and breastfeeding
Human data in pregnancy are limited, and in monkey studies Rystiggo caused pregnancy loss and weaker immune systems in offspring.
- It is not known whether Rystiggo passes into breast milk.
- A pregnancy registry takes reports through UCBCares at 1-844-599-2273.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of an allergic reaction
Swelling, including deep swelling under the skin called angioedema, or a rash.
- In the trials these reactions appeared anywhere from 1 day to 2 weeks after a dose.
- The label tells patients to contact their healthcare provider immediately.FDA label
Signs of aseptic meningitis
Severe headache, a stiff neck, drowsiness, fever, sensitivity to light, painful eye movements, nausea or vomiting.
- UCB says to tell your healthcare provider right away if any of these develop during treatment.UCB FAQs
Signs of infection
Fever, chills, frequent or painful urination, cough, runny nose, wheezing, shortness of breath, tiredness, sore throat or phlegm.
- UCB says to tell your healthcare provider right away.
- In the studies, the most common infections were upper respiratory infections, COVID-19, urinary infections and herpes simplex.UCB FAQs
Headache, diarrhea and fever
In the main trial, headache occurred in 44% on Rystiggo against 19% on placebo, diarrhea in 20% against 13%, and fever in 17% against 2%.
- Shingles has also been reported since approval, according to the label.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe FEP policy below asks for a positive AChR or MuSK antibody test, a symptom score, an IgG level and one earlier treatment that did not work. If a request is denied, UCB says your healthcare provider starts the appeal, and your Care Coordinator keeps you updated.FEP Blue policy
- The prescription went to a pharmacy outside the networkRystiggo comes through a limited network of specialty pharmacies, including CVS Specialty, KabaFusion, Optum Infusion and SoleoHealth. Clinics can also buy it from an authorized distributor and bill your plan, so this is a routing question rather than a denial.How to acquire
- Home infusion is not coveredUCB says home infusions with a nurse depend on your insurance coverage. An infusion center, doctor's office or hospital clinic may still be covered, and ONWARD's Care Coordinator can help find one near you.UCB dosing page
- A copay you cannot payWith commercial insurance, UCB's copay program may bring the cost as low as $0 per dose. Medicare, Medicaid, TRICARE, VA and other government plans are excluded by its terms. Eligible patients may get Rystiggo free for up to 12 months through the Patient Assistance Program.UCB cost page
- You live in Massachusetts, Minnesota or Rhode IslandThe copay program's terms exclude residents of these 3 states from help with administration costs. The clinic's infusion fee may therefore fall on you, so ask ONWARD about other options.UCB cost page
- You do not have AChR or MuSK antibodiesThe label covers only adults who test positive for one of these 2 antibodies, and the FEP policy requires the same. Other treatment choices are a conversation for your neurologist.FDA label
- Renewal refused after the first approvalThe FEP policy below approves 6 months first, then renews for 12 months if the MG-ADL or QMG score dropped 2 points or more. Keeping the score sheets from cycle 1 makes that renewal easier for the office.FEP Blue policy
Blue Cross Blue Shield Federal Employee Program prior authorization policy, October 1, 2026
- Age 18 or older, with generalized myasthenia gravis and a positive AChR or MuSK antibody test
- Myasthenia Gravis Foundation of America class II to IVa
- A baseline MG-ADL score of 3 or more, with at least 3 points from symptoms outside the eyes, or a QMG score above 9
- A serum IgG level of 5.5g/L or higher
- An acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate or cyclophosphamide did not work well enough, was not tolerated or could not be used (one of these)
- Not given at the same time as live or live-attenuated vaccines
Approval length. Six months at first, then 12 months at a time if the MG-ADL or QMG score fell 2 points or more, with no unacceptable side effects.
This policy was last reviewed on September 17, 2026 and cites the December 2025 Rystiggo label, so it matches the current approved use. In September 2025 FEP dropped its earlier rule requiring 2 failed treatments and added the QMG score as an option. It sets no minimum gap between cycles of its own. It is here as an example of what a plan asks for, not as a rule. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A medically trained ONWARD Care Coordinator personally assigned to you, who does not give medical advice
- Help reviewing insurance coverage and potential financial assistance options, even if you are uninsured
- Tools and resources to help you start and continue your prescribed treatment
- Information on symptom tracking and ongoing treatment support
- Sign-up through your doctor, a Start Form from ucbONWARD.com, or a call to 1-844-ONWARD-1
Details as the drugmaker publishes them. ONWARD
Five questions for the pharmacist or the support line
- Which specialty pharmacy or infusion center is handling my doses, and what number will they call me from?
- Will my infusions be at a clinic or at home with a nurse, and does my plan cover that choice?
- Is all of cycle 1 approved, all 6 weekly vials, and when should cycle 2 be ordered?
- If my infusion day falls on a holiday or I am traveling, how many days late can it be given?
- I take IVIG or another antibody medicine. Does my neurologist need to know before my next cycle?
- Does my copay help cover the clinic's administration fee as well as the drug, given the state I live in?
Questions people ask in the first weeks
How long does it take to start Rystiggo after it is prescribed?
There is no fixed number of days between the prescription and the first dose. Enrollment, the benefits check, prior authorization and booking an infusion site each take their own time. Your ONWARD Care Coordinator keeps you updated while these steps move forward.
How often is Rystiggo given for myasthenia gravis?
In cycles of 1 infusion a week for 6 weeks, followed by a break. The neurologist times later cycles from a clinical evaluation of how you are doing. The label says starting a new cycle sooner than 63 days after the previous one began has no established safety.
Can I give Rystiggo to myself at home?
Not under the US label, which says only a healthcare provider should prepare and infuse it. A nurse may give it at home if your insurance covers that. UCB announced in January 2025 that European regulators backed self-infusion after training, with a pump or a syringe pushed by hand.
Do I need vaccines before starting Rystiggo?
UCB says Rystiggo has no vaccine requirement before treatment. The label asks the doctor to check age-appropriate vaccines before each new cycle and says live vaccines are not recommended during treatment.
Do I need blood tests on Rystiggo?
The label sets no scheduled blood test during treatment. Some insurers ask for one before approval, though, and the FEP policy below requires an IgG level of at least 5.5g/L.
What if I have an infection when a dose is due?
The label says to delay the dose until the infection has resolved. Call the neurologist's office before the appointment rather than after it, so the visit can be moved.
Why does headache come up so often with Rystiggo?
Headache was the most common side effect in the main trial, in 44% on Rystiggo against 19% on placebo. A severe headache with fever, a stiff neck or light sensitivity can also signal aseptic meningitis, which needs a call to your care team right away.
Is Rystiggo approved if I do not have AChR or MuSK antibodies?
No, the label covers only adults with generalized myasthenia gravis who test positive for AChR or MuSK antibodies. UCB says Rystiggo is the first FDA-approved treatment for both AChR and MuSK antibody positive gMG in adults.
Free email alert
Hear when the Rystiggo label changes
One email the day the FDA revises the Rystiggo label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Rystiggo only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Generalized myasthenia gravis for new trials, FDA decisions and label changes for every treatment.
Sources
- RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use, prescribing information, revised December 2025 (DailyMed SPL version 11), UCB, via DailyMed, October 23, 2026.
- RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use, prescribing information, revised 12/2025 (BLA 761286/S-007), FDA, Drugs@FDA, December 9, 2025.
- RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use, prescribing information, revised 6/2024 (BLA 761286/S-001), FDA, Drugs@FDA, June 14, 2024.
- Dosing and Administration of RYSTIGGO® Infusion For gMG, UCB, November 7, 2026.
- RYSTIGGO Frequently Asked Questions, UCB, November 7, 2026.
- Cost and Insurance Information for RYSTIGGO® (rozanolixizumab-noli), UCB, November 7, 2026.
- ONWARD® Support For RYSTIGGO Treatment, UCB, November 7, 2026.
- ONWARD® | Care Coordinators - Treatment Preparation, UCB, November 7, 2026.
- ONWARD® | Finances - Insurance and RYSTIGGO, UCB, November 7, 2026.
- Start Form for RYSTIGGO® (rozanolixizumab-noli) Injection For Subcutaneous Use (US-RZ-2600436), UCB, July 7, 2026.
- How to Acquire RYSTIGGO, UCB, July 16, 2026.
- Coding and Billing Guide for the use of RYSTIGGO (rozanolixizumab-noli) in adult patients with generalized myasthenia gravis (gMG), UCB, July 15, 2024.
- Pharmacy Policy 5.85.050, Rystiggo (rozanolixizumab-noli), Blue Cross Blue Shield Federal Employee Program, October 1, 2026.
- RYSTIGGO®▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods, UCB, January 31, 2025.
- BLA 761286/S-007 supplement approval letter, pregnancy exposure registry and postmarketing herpes zoster, FDA, December 9, 2025.
- BLA 761286 approval letter, Rystiggo (rozanolixizumab-noli) injection, FDA, June 26, 2023.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing neurologist. Found an error? Use the report link in the footer and it will be checked against the source.